Join to View Full Profile
1624 South I StreetSuite 102Tacoma, WA 98405
Phone+1 253-383-3366
Fax+1 253-383-3376
Dr. Chaves is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Boston University Medical CenterResidency, Internal Medicine, 2005 - 2008
McGovern Medical School at UTHealthClass of 2005
Certifications & Licensure
WA State Medical License 2011 - 2025
CT State Medical License 2010 - 2011
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013
Clinical Trials
- Phase 1 Study of ONT-10 in Patients With Solid Tumors Start of enrollment: 2013 Mar 01
- Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors Start of enrollment: 2013 Mar 29
- PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsPembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D.Richard Kim, Mustapha Tehfe, Petr Kavan, Jorge Chaves, Jeremy S Kortmansky
Clinical Colorectal Cancer. 2024-06-01 - Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E.Eric X Chen, Petr Kavan, Mustapha Tehfe, Jeremy S Kortmansky, Michael B Sawyer
Clinical Colorectal Cancer. 2024-06-01 - 63 citationsZanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and...Funda Meric-Bernstam, Muralidhar Beeram, Erika Hamilton, Do-Youn Oh, Diana L Hanna
The Lancet. Oncology. 2022-12-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
